Disease | lymphoma |
Phenotype | C0149925|small cell lung cancer |
Sentences | 3 |
PubMedID- 25676399 | Background: besides epidermal growth factor receptor (egfr) mutation, the non-small cell lung cancer (nsclc) of anaplastic lymphoma kinase (alk) rearrangement becomes another important clinical subtype. |
PubMedID- 25170012 | Fda approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. |
PubMedID- 22465695 | Fluorescence in situ hybridization (fish) is currently used to detect non-small cell lung cancer (nsclc) patients with anaplastic lymphoma kinase (alk) gene rearrangement, who are candidates for alk inhibitor therapy. |
Page: 1